Maryland to receive $13 million in opioid settlements with drugmakers

Todd Karpovich, The Baltimore Sun on Jul 24, 2026

By clicking submit, I authorize Arcamax and its affiliates to: (1) use, sell, and share my information for marketing purposes, including cross-context behavioral advertising, as described in our Privacy Policy , (2) add to information that I provide with other information like interests inferred from web page views, or data lawfully obtained from data brokers, such as past purchase or location data, or publicly available data, (3) contact me or enable others to contact me by email or other means with offers for different types of goods and services, and (4) retain my information while I am engaging with marketing messages that I receive and for a reasonable amount of time thereafter. I understand I can opt out at any time through an email that I receive, or by clicking here

BALTIMORE — Maryland will receive more than $13 million as part of a multistate settlement with seven opioid manufacturers accused of helping fuel the nation’s opioid epidemic, Attorney General Anthony G. Brown announced.

The settlements with Alvogen, Amneal, Apotex, Hikma, Mylan, Sun and Zydus resolve allegations that the companies’ manufacturing, marketing and sales practices contributed to the widespread diversion of prescription opioids, including oxycodone, hydrocodone and fentanyl patches.

The agreements, which have been entered in Frederick County Circuit Court, will provide more than $13 million to Maryland for opioid abatement efforts, including treatment and recovery programs, according to Brown. The opioid manufacturers could not immediately be reached for comment.

“Maryland communities are still living with addiction and loss caused by the opioid crisis,” Brown said in a statement. “These settlements will fund treatment and recovery that helps Marylanders break the cycle of addiction and also require safeguards that keep the drug companies responsible for the crisis from fueling another.”

Under the settlements, Mylan will pay Maryland about $6 million over 10 years, while Amneal will pay about $2.45 million over the same period. Hikma will pay about $2.07 million, Apotex about $1.37 million, Sun about $667,000, Alvogen about $402,000 and Zydus about $318,000. The payments from all but Mylan and Amneal will be made in a single year.

In addition to the financial payments, the companies agreed to restrictions on their opioid businesses. The settlements prohibit the manufacturers from promoting or marketing opioid products to prescribers or patients, bar them from manufacturing, promoting or distributing oxycodone pills exceeding 40 milligrams, and prohibit tying sales staff compensation or discipline to opioid sales volume.

The companies also must maintain systems to monitor and report suspicious orders of opioid products.

The settlements resolve allegations only and are not findings of liability.

_____